RCT: Paclitaxel and Carboplatin noninferior to Paclitaxel and Ifosfamide in patients with carcinosarcoma of the uterus or ovary.
18 Jan, 2022 | 09:10h | UTCRandomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)